Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOC-R01 lenalidomide/ibrutinib plus R-MPV for newly diagnosed primary CNS lymphoma
2019-003632-23Phase 2Active
- Sponsor
- Institut Curie
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide and ibrutinib in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Institut Curie. Primary endpoints: Dose-limiting toxicity during first cycle and Complete response rate after 2 cycles. Started Apr 2020; status: active.
02
Drugs
lenalidomideibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2019-003632-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003632-23.